Mark Berman, MD
Ophthalmology · Sandy Springs, GANPI 1821095373
Payments from drug & device makers
Across 129 payments — averaging $46.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Carl Zeiss Meditec USA, Inc.$1K
- Johnson & Johnson Surgical Vision, Inc.$784
- Alcon$566
- Coopervision Inc.$500
- Bausch & Lomb Americas Inc.$318
- plus $2K from 16 others
What the payments were for
- Food & beverage$4,52076%
- Education$5008%
- Other$93016%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $1,134 |
| Carl Zeiss Meditec USA, Inc. | 2 | $1,099 |
| Johnson & Johnson Surgical Vision, Inc. | 20 | $784 |
| Alcon | 12 | $566 |
| Coopervision Inc. | 2 | $500 |
| Bausch & Lomb Americas Inc. | 13 | $318 |
| NEW World Medical,inc. | 2 | $247 |
| Tarsus Pharmaceuticals, Inc. | 7 | $211 |
| Amgen(2 entities) | 5 | $210 |
| Eyevance Pharmaceuticals LLC | 1 | $172 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $154 |
| Carl Zeiss Meditec, Inc. | 1 | $134 |
| Harrow Eye, LLC | 1 | $102 |
| Oyster Point Pharma, Inc. | 5 | $98 |
| Thea Pharma Inc. | 2 | $55 |
| Dompe US, Inc. | 3 | $53 |
| Sandoz | 1 | $27 |
| Kala Pharmaceuticals, Inc. | 1 | $19 |
| Sight Sciences, Inc. | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Omeros Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMERA 700$1,099
- MiSight Contact Lens$500
- DURYSTA$236
- Tobradex ST$172
- Clareon$149
- Kahook Dual Blade$148
- Clearpath$148
- Ahmed Glaucoma Valve$148
- Streamline$148
- LenSx$142
- OPMI Lumera$134
- TEPEZZA$123
- Tecnis IOL$118
- IC-8 Apthera IOL$105
- Tecnis Toric 1-piece IOL$104
- VEVYE$102
- Tecnis 1-piece IOL$102
How this compares
$5,950 in reported general payments places this provider in the 75th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 263 | $155,746 |
| RestasisCyclosporine | 92 | $107,837 |
| CombiganBrimonidine Tartrate/Timolol | 118 | $48,791 |
| RhopressaNetarsudil Mesylate | 85 | $38,178 |
| XdemvyLotilaner | 15 | $28,062 |
| Cyclosporine | 37 | $22,552 |
| XiidraLifitegrast | 20 | $21,578 |
| Travoprost | 115 | $20,217 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 79 | $19,248 |
| Latanoprost | 1,250 | $16,908 |
| RocklatanNetarsudil Mesylat/Latanoprost | 27 | $16,058 |
| Prednisolone Acetate | 431 | $13,694 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 38 | $13,136 |
| Alphagan PBrimonidine Tartrate | 29 | $12,792 |
| Brinzolamide | 34 | $8,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,134 | $325,167502 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $18 | $54,236112 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $211 | $28,06215 claims |
| Bausch & Lomb Americas Inc.Xiidra | $318 | $21,57820 claims |
| AlconSimbrinza | $566 | $13,13638 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Loteprednol Etabonate | $154 | $12,00853 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $98 | $7,22911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Sandy Springs
- Dana WallaceSandy Springs$222K
- Robert BlasbergSandy Springs$59K
- Jessica McCluskeySandy Springs$23K
- Paul KaufmanSandy Springs$20K
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.